Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS) and Seattle Genetics (NASDAQ: SGEN)

By Carrie Williams

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Exact Sciences (NASDAQ: EXAS) and Seattle Genetics (NASDAQ: SGEN).

Exact Sciences (NASDAQ: EXAS)

Exact Sciences (NASDAQ: EXAS) received a Hold rating and a $56 price target from Robert W. Baird analyst Catherine Schulte today. The company’s shares closed on Friday at $60.37, close to its 52-week high of $63.60.

According to TipRanks.com, Schulte is a 4-star analyst with an average return of 15.0% and a 64.3% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Bio-Techne Corporation, and Oxford Immunotec.

Currently, the analyst consensus on Exact Sciences is Strong Buy and the average price target is $59.50, representing a -1.4% downside.

In a report issued on November 1, BTIG also downgraded the stock to Hold.
Seattle Genetics (NASDAQ: SGEN)

RBC Capital analyst Kennen MacKay reiterated a Buy rating on Seattle Genetics (NASDAQ: SGEN) today and set a price target of $69. The company’s shares closed on Friday at $57.96.

According to TipRanks.com, MacKay is a 5-star analyst with an average return of 25.2% and a 61.9% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Five Prime Therapeutics, and Akebia Therapeutics.

Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $62.91.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.